https://mindmedicinelaw.com/briefing/fda-pediatric-advisory-committee-meeting-implications-for-psychedelic-research-20260728-26614The Psychedelic Journalen2026-07-28T15:06:11.997235+00:00FDA Pediatric Advisory Committee Meeting: Implications for Psychedelic ResearchFDA Pediatric Advisory Committee, psychedelic research minors, pediatric psychedelic therapies, FDA public meeting, psychedelic regulatory issues, pediatric clinical trials, psychedelic safety children, public health policy psychedelicshttps://mindmedicinelaw.com/briefing/insights-from-psychedelic-clinical-trial-design-review-20260725-26399The Psychedelic Journalen2026-07-27T15:05:44.636561+00:00Insights from Psychedelic Clinical Trial Design Reviewpsychedelic clinical trials, trial design, psychedelic research, clinical methodologies, adaptive trial design, research protocols, psychedelic therapies, long-term effects, safety protocols, scientific rigorhttps://mindmedicinelaw.com/briefing/ect-alters-brain-networks-in-depression-new-insights-20260724-26179The Psychedelic Journalen2026-07-26T22:06:31.655417+00:00ECT Alters Brain Networks in Depression: New InsightsECT, brain networks, depression treatment, neuroimaging, functional connectivity, subcortical regions, default network, clinical research, therapeutic strategies, personalized treatmenthttps://mindmedicinelaw.com/briefing/evolutionary-theory-of-nightmares-and-clinical-implications-20260724-26167The Psychedelic Journalen2026-07-26T22:06:23.865984+00:00Evolutionary Theory of Nightmares and Clinical Implicationsevolutionary theory, nightmares, dream engineering, clinical interventions, neurocognitive mechanisms, emotional adaptation, threat rehearsal, pathological nightmares, adaptive dreaming, sleep disruptionhttps://mindmedicinelaw.com/briefing/phytochemicals-as-nmdar-inhibitors-potential-in-cns-therapeutics-20260724-26168The Psychedelic Journalen2026-07-26T22:06:17.480607+00:00Phytochemicals as NMDAR Inhibitors: Potential in CNS Therapeuticsphytochemicals, NMDAR inhibitors, neuroprotection, excitotoxicity, CNS therapeutics, neurodegenerative diseases, glutamate receptors, clinical trials, drug discovery, neuroinflammationhttps://mindmedicinelaw.com/briefing/doi-s-impact-on-cortical-network-modularity-in-mice-20260724-26169The Psychedelic Journalen2026-07-26T22:05:56.968941+00:00DOI's Impact on Cortical Network Modularity in MiceDOI, cortical network modularity, 5-HT2A receptor, thalamo-cortical interactions, psychedelic research, brain connectivity, calcium imaging, therapeutic applicationshttps://mindmedicinelaw.com/briefing/trump-s-executive-order-and-its-impact-on-psychedelic-therapy-20260722-26585The Psychedelic Journalen2026-07-27T22:04:02.298858+00:00Trump's Executive Order and Its Impact on Psychedelic Therapypsychedelic therapy, executive order, Trump, regulatory processes, FDA, DEA, mental health treatmenthttps://mindmedicinelaw.com/briefing/bacterial-dmt-production-breakthrough-in-scalable-synthesis-20260721-26148The Psychedelic Journalen2026-07-26T22:06:04.321243+00:00Bacterial DMT Production: Breakthrough in Scalable SynthesisDMT production, bacterial synthesis, Escherichia coli, tryptamine, methyltransferase, pharmaceutical applications, neuroscience research, clinical trials, psychedelic compounds, scalable productionhttps://mindmedicinelaw.com/briefing/s-ketamine-and-s-hnk-new-pathways-in-depression-treatment-20260721-26189The Psychedelic Journalen2026-07-26T22:05:49.361690+00:00S-ketamine and S-HNK: New Pathways in Depression TreatmentS-ketamine, S-HNK, depression treatment, neuroinflammation, TLR4 signaling, PPARα modulation, psychiatric disorders, clinical trials, antidepressant pathways, prefrontal cortex